## Cancer in Manitoba

2017 ANNUAL STATISTICAL REPORT



# Department of Epidemiology and Cancer Registry



## **Department of Epidemiology** and Cancer Registry

<b>Table of Contents</b>	
Introduction to the Data	2
Manitoba's Cancer Profile	
Facts & Figures	3
Most Common Cancers, 2016	3
Cancer Incidence by Site	4
Manitaha Cancar Datas hu Dagianal	
Manitoba Cancer Rates by Regional Health Authority (Incidence)	5
Cancer Incidence—Cases & Rates by Site	6
Tumour Staging by Site	8
Deaths by Underlying Cause in	
Manitoba (Mortality)	11
Appendix 1	
International Classification	
Of Disease for Oncology, 3rd Edition	12

#### Vision

Working together, we will reduce the impact of cancer on all Manitobans.

#### Mission

Through early detection, care, research, education, and public outreach, CancerCare Manitoba will contribute to the prevention of cancer and improve the outcomes and quality of life for Manitobans with cancer or blood disorders.

#### Introduction to the Data

The Manitoba Cancer Registry is an essential tool for evidence-based, data-driven decision making that has an immense impact on treatment and research. This year's report is based on the following information.

NOTE: All statistics in the body of this report only include Manitoba residents.

#### Manitoba Cancer Registry data is used for:

- · health care planning and monitoring
- · surveillance and studies on the causes and prevention of cancer, cancer clusters, treatment patterns, outcomes and survival
- · patient care
- · quality assurance
- · reporting to the Canadian Cancer Registry, the North American Association of Central Cancer Registries and the International Association of **Cancer Registries**

#### Information sources include:

- provincial cytology and pathology departments
- admission/separation data from the provincial hospital abstracting system
- Manitoba Provincial Client Registry
- letters and "Report of Malignant Neoplasm Forms" from physicians and other health care providers
- · hospital health records
- correspondence from other provincial and territorial cancer registries on Manitoba residents diagnosed and/or treated in those iurisdictions

#### Incidence data

Incidence refers to the number of new cases of cancer diagnosed in Manitoba every year. Cancer cases referenced were diagnosed in the 2017 calendar year. Incidence is also provided by stage of disease at diagnosis.

The Manitoba Cancer Registry uses disease site groupings according to the International Classification of Diseases for Oncology Third Edition (ICD-O<sub>3</sub>), based on Surveillance Epidemiology and End Results (SEER) Groups. See Appendix 1 for the primary site groupings used for incidence.

#### Mortality data

Mortality information refers to Manitobans who died of cancer in the 2017 calendar year, however, those patients may not have been diagnosed in 2017. The Vital Statistics Agency of Manitoba reported cancer as the leading cause of death in the province. In 2017, there were 2,456 deaths due to invasive cancer (age standardized rate – 181.0 per 100,000). The totals in the summary on page 11 include all cancer deaths occurring in Manitoba.

#### Rates

Incidence counts and rates are presented in this report. Annual age-standardized rates are per 100,000 population and allow for comparison of cancer rates in different regions with different age structures. Rates are age-standardized (using the direct method) to the 2011 Manitoba population.

#### Staging data

The Manitoba Cancer Registry implemented stage data collection for all cases of cancer (excluding non-melanoma skin) diagnosed January 1, 2004 and forward. This data is consistent with the American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 7th edition.

In this report, stage data is shown for all disease site groups with a cancer incidence of 40 cases per year or more and is represented using pie charts. Stage information, along with frequency of incidence for each of these sites, can also be found in table format on page 8.

#### Population data

Data are based on Manitoba estimates provided by Manitoba Health, Seniors and Active Living.

Additional statistical information is available upon request. Please contact the Manitoba Cancer Registry at:

> 1-877-787-1272 (toll-free), or CCMBepireg@cancercare.mb.ca

#### **Manitoba's Cancer Profile**

## **Facts & Figures**

#### Manitoba's cancer profile

Cancer is a significant health issue. In 2017, 11,893 Manitobans were diagnosed with cancer:

- 6,661 invasive cancers
- 1931 in situ (confined to the area of origin)
- 311 unspecified cancers
- 126 benign brain and CNS (central nervous system)

In this same year, **2,456** people died from the disease.

The number of cancer cases in Manitoba is influenced by three factors:

- the age of the population
- the size of the population
- risk factors such as unhealthy living (including smoking, poor diet, inactivity, sun exposure), some environmental carcinogens, genetic predisposition and not being screened.


## Most Common Cancer Diagnoses, 2017


#### Incidence


Male		Female		Total	
SITE	CASES	SITE	CASES	SITE	CASES
Prostate	722	Breast	890	Breast	893
Colorectal	440	Lung & bronchus	463	Lung & bronchus	888
Lung & bronchus	425	Colorectal	375	Colorectal	815
Non-Hodgkin lymphoma	170	Corpus uteri	307	Prostate	722
Melanoma of the skin	164	Non-Hodgkin lymphoma	152	Non-Hodgkin lymphoma	322
Kidney	161	Melanoma of the skin	133	Corpus uteri	307
Bladder	127	Thyroid	122	Melanoma of the skin	297
Pancreas	94	Pancreas	108	Kidney	226
Stomach	64	Kidney	65	Pancreas	202
Liver	63	Ovary	62	Bladder	160

## **Cancer Incidence by Site**


#### Invasive cancers only







## **Manitoba Cancer Rates by Regional Health Authority**




## 2017 All Invasive Cancers Female *Incidence*

Age-standardized rate per 100,000 Standard population: Manitoba 2011 Out of province residents excluded

## 2017 All Invasive Cancers Male Incidence

Age-standardized rate per 100,000 Standard population: Manitoba 2011 Out of province residents excluded



#### Cancer Incidence - Cases and Rates in Manitoba by Site, 2017

											А	ge grou	ıp										Т	otal Cou	ınt		ASIR*	
	Cancer Site		00-29			30-39			40-49			50-59	I		60-69			70-79	I		80+			ı				
		М	F	Т	М	F	Т	М	F	Т	М	F	Т	М	F	Т	М	F	Т	М	F	Т	М	F	Т	М	F	Т
	Lip	0	0	0	0	1	1	3	0	3	3	0	3	11	2	13	14	2	16	8	6	14	39	11	50	6.08	1.41	3.58
	Tongue	0	0	0	1	1	2	6	1	7	7	2	9	15	2	17	8	2	10	4	2	6	41	10	51	6.20	1.38	3.68
	Major salivary gland	1	2	3	1	1	2	0	0	0	0	1	1	2	0	2	0	0	0	1	1	2	5	5	10	0.77	0.73	0.73
pharynx	Floor of mouth	0	0	0	0	0	0	0	0	0	0	1	1	2	1	3	1	0	1	0	0	0	3	2	5	0.41	0.28	0.34
Buccla cavity & pharynx	Gum & other mouth	0	0	0	0	0	0	0	0	0	3	3	6	1	2	3	1	2	3	0	2	2	5	9	14	0.74	1.23	1.02
Buccla	Nasopharynx	0	0	0	0	0	0	0	0	0	2	0	2	5	0	5	0	1	1	0	0	0	7	1	8	0.98	0.13	0.55
	Oropharynx	0	0	0	1	0	1	0	0	0	2	2	4	5	1	6	1	1	2	0	0	0	9	4	13	1.26	0.56	0.91
	Hypopharynx	0	0	0	0	0	0	1	0	1	1	0	1	2	0	2	1	0	1	1	0	1	6	0	6	0.94	0.00	0.44
	Other buccal cavity & pharynx	0	0	0	0	0	0	2	1	3	10	1	11	16	3	19	2	2	4	0	0	0	30	7	37	4.31	0.96	2.62
	Esophagus	0	0	0	0	0	0	2	2	4	10	2	12	17	4	21	14	7	21	11	3	14	54	18	72	8.43	2.42	5.14
	Stomach	0	2	2	1	1	2	2	2	4	11	5	16	19	8	27	19	11	30	12	9	21	64	38	102	9.91	5.12	7.29
	Small intestine	0	0	0	1	0	1	1	1	2	2	3	5	3	5	8	3	1	4	2	2	4	12	12	24	1.86	1.66	1.73
	Colon excluding rectum	3	2	5	4	8	12	11	11	22	36	34	70	70	59	129	97	62	159	63	90	153	284	266	550	44.61	35.38	39.61
Digestive	Rectum & rectosigmoid	0	3	3	1	1	2	12	14	26	30	27	57	47	25	72	42	20	62	24	19	43	156	109	265	24.01	15.28	19.20
Dige	Anus	0	0	0	0	0	0	1	0	1	5	3	8	3	4	7	2	2	4	0	2	2	11	11	22	1.62	1.49	1.59
	Liver	0	0	0	0	0	0	3	0	3	15	6	21	22	6	28	15	6	21	8	3	11	63	21	84	9.55	2.84	5.98
	Gallbladder	0	0	0	0	1	1	1	0	1	2	3	5	6	6	12	4	6	10	0	1	1	13	17	30	1.85	2.26	2.07
	Pancreas	0	0	0	1	0	1	2	5	7	17	12	29	28	28	56	31	32	63	15	31	46	94	108	202	14.36	14.27	14.40
	Other digestive system	0	0	0	0	0	0	2	1	3	2	4	6	20	12	32	10	9	19	15	11	26	49	37	86	7.86	4.87	6.14
>	Larynx	0	0	0	0	0	0	0	0	0	3	1	4	8	3	11	12	0	12	2	0	2	25	4	29	3.65	0.54	1.99
Respiratory	Lung & bronchus	0	0	0	5	4	9	4	6	10	44	68	112	129	127	256	141	155	296	102	103	205	425	463	888	66.64	61.05	62.84
	Other respiratory system	2	0	2	0	0	0	2	1	3	1	1	2	1	1	2	1	0	1	3	0	3	10	3	13	1.68	0.45	0.99
	Bones & joints	1	1	2	0	0	0	0	1	1	1	1	2	2	1	3	1	1	2	1	1	2	6	6	12	0.92	0.86	0.88
ft tissue t)	Soft tissue (Including heart)	4	2	6	3	2	5	4	2	6	3	4	7	3	2	5	7	3	10	6	5	11	30	20	50	4.78	2.81	3.71
Mesothelial & soft tissue (inc. heart)	Kaposi sarcoma	2	0	2	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	3	0	3	0.46	0.00	0.23
Mesoth (	Mesothelioma	0	0	0	0	0	0	1	0	1	1	0	1	0	0	0	7	2	9	6	1	7	15	3	18	2.56	0.38	1.31
	Melanoma of the skin	0	6	6	5	7	12	7	10	17	41	25	66	40	33	73	43	27	70	28	25	53	164	133	297	25.48	18.29	21.46
	Breast	0	7	7	0	32	32	0	96	96	0	196	196	1	237	238	2	202	204	0	120	120	3	890	893	0.42	123.24	64.65
	Cervix uteri	0	2	2	0	13	13	0	13	13	0	9	9	0	5	5	0	4	4	0	3	3	0	49	49	0.00	7.24	0.00
ital	Corpus uteri	0	1	1	0	8	8	0	22	22	0	92	92	0	96	96	0	57	57	0	31	31	0	307	307	0.00	42.71	0.00
Female genital	Uterus, NOS	0	0	0	0	0	0	0	1	1	0	0	0	0	1	1	0	0	0	0	3	3	0	5	5	0.00	0.68	0.00
Fer	Ovary	0	1	1	0	4	4	0	8	8	0	14	14	0	19	19	0	12	12	0	4	4	0	62	62	0.00	8.70	0.00
	Other female genital system	0	0	0	0	2	2	0	4	4	0	7	7	0	12	12	0	10	10	0	13	13	0	48	48	0.00	6.49	0.00

											А	ge grou	ıp															
	Cancer Site		00-29			30-39			40-49			50-59			60-69			70-79			80+		Тс	otal Cou	nt		ASIR*	
		M	F	T	М	F	T	М	F	Т	M	F	Т	М	F	Т	М	F	Т	М	F	Т	М	F	T	М	F	Т
	Prostate	0	0	0	0	0	0	6	0	6	101	0	101	249	0	249	242	0	242	124	0	124	722	0	722	110.02	0.00	0.00
Male genital	Testis	10	0	10	12	0	12	10	0	10	4	0	4	0	0	0	0	0	0	0	0	0	36	0	36	5.46	0.00	0.00
Male	Penis	0	0	0	1	0	1	0	0	0	1	0	1	4	0	4	7	0	7	1	0	1	14	0	14	2.03	0.00	0.00
	Other male genital system	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	0	3	0	0	0	3	0	3	0.42	0.00	0.00
	Bladder	0	0	0	0	1	1	2	1	3	10	3	13	33	7	40	47	9	56	35	12	47	127	33	160	20.23	4.33	11.39
Urinary	Kidney	3	2	5	2	0	2	14	8	22	36	16	52	47	17	64	41	10	51	18	12	30	161	65	226	24.46	9.10	16.34
Uni	Ureter	0	0	0	0	0	0	0	0	0	1	0	1	2	1	3	1	1	2	3	1	4	7	3	10	1.19	0.38	0.72
	Other urinary system	0	0	0	0	0	0	1	0	1	0	0	0	2	0	2	1	0	1	5	1	6	9	1	10	1.62	0.13	0.76
	Eye	0	0	0	0	0	0	0	0	0	2	0	2	1	0	1	2	1	3	0	0	0	5	1	6	0.73	0.13	0.42
Brain & other CNS	Brain	5	9	14	3	0	3	3	2	5	9	7	16	13	7	20	12	8	20	9	6	15	54	39	93	8.37	5.48	6.75
Brai	Other nervous system	2	1	3	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	1	0	1	3	2	5	0.50	0.32	0.39
Endocrine	Thyroid	4	13	17	3	17	20	5	30	35	8	24	32	8	24	32	3	9	12	2	5	7	33	122	155	5.00	18.00	11.55
Endo	Other endocrine	0	2	2	2	0	2	1	0	1	1	0	1	2	0	2	0	3	3	1	0	1	7	5	12	1.08	0.68	0.86
в	Hodgkin lymphoma	10	5	15	5	5	10	2	0	2	3	3	6	2	2	4	4	0	4	2	1	3	28	16	44	4.23	2.32	3.23
Lymphoma	Non-Hodgkin lymphoma	3	6	9	6	7	13	12	7	19	26	17	43	53	47	100	44	36	80	26	32	58	170	152	322	26.05	20.38	22.99
	Multiple myeloma	0	0	0	1	0	1	1	2	3	7	9	16	19	11	30	18	10	28	14	8	22	60	40	100	9.40	5.42	7.13
	Acute lymphocytic leukemia	6	11	17	1	0	1	0	0	0	0	0	0	1	1	2	0	0	0	0	0	0	8	12	20	1.16	1.83	1.48
	Chronic lymphocytic leukemia	0	0	0	0	0	0	4	0	4	6	5	11	21	8	29	12	3	15	12	5	17	55	21	76	8.60	2.82	5.43
Leukemias	Acute myeloid leukemia	1	1	2	2	3	5	1	1	2	7	4	11	3	5	8	8	8	16	3	8	11	25	30	55	3.84	4.03	3.98
Leuk	Chronic myeloid leukemia	0	1	1	0	1	1	0	1	1	3	3	6	3	1	4	4	1	5	3	5	8	13	13	26	0.00	0.13	0.07
	Other leukemias	1	0	1	0	0	0	1	0	1	0	0	0	4	0	4	2	1	3	2	1	3	10	2	12	2.06	1.82	1.92
	Acute monocytic leukemia	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	1	1.55	0.25	0.86
	Other ill defined & unknown	2	2	4	1	0	1	6	5	11	13	10	23	43	25	68	45	26	71	29	41	70	139	109	248	21.61	14.40	17.79
	TOTAL - ALL INVASIVE	60	82	142	63	120	183	137	260	397	490	628	1118	988	861	1849	975	766	1741	602	629	1231	3315	3346	6661	511.92	457.68	477.79
	Non-Melanoma skin & in situ skin	1	7	8	15	41	56	70	98	168	243	238	481	498	362	860	629	393	1022	521	460	981	1977	1599	3576	315.61	214.67	257.72
	Breast in situ	0	1	1	0	2	2	0	10	10	1	40	41	0	39	39	0	22	22	0	7	7	1	121	122	0.15	17.00	8.80
	Cervix in situ	0	175	175	0	133	133	0	50	50	0	37	37	0	10	10	0	1	1	0	0	0	0	406	406	0.00	61.23	0.00
Insitu	Prostate in situ	0	0	0	0	0	0	1	0	1	2	0	2	8	0	8	5	0	5	2	0	2	18	0	18	2.67	0.00	0.00
	Bladder in situ	0	0	0	1	1	2	5	3	8	15	7	22	31	12	43	49	14	63	34	14	48	135	51	186	21.45	6.81	13.32
	Colorectal in situ	0	0	0	2	2	4	7	8	15	30	17	47	81	42	123	70	44	114	28	17	45	218	130	348	32.67	17.37	24.40
	Other in situ (Excl. Breast, Skin, Cervix, Prostate, Bladder, Colorectal)	3	2	5	3	5	8	3	6	9	10	25	35	11	27	38	16	12	28	8	8	16	54	85	139	8.31	11.90	10.02
	TOTAL - ALL INVASIVE & IN SITU	64	267	331	84	304	388	223	435	658	791	992	1783	1617	1353	2970	1744	1252	2996	1195	1135	2330	5718	5738	11456	892.79	786.66	823.66
	Brain uncertain & unspecified	0	1	1	0	4	4	0	3	3	2	0	2	2	0	2	2	1	3	0	1	1	6	10	16	0.86	1.47	1.17
	Neoplasms (Uncertain & unspecified, excluding brain)	11	11	22	2	15	17	4	23	27	19	25	44	25	30	55	40	30	70	29	31	60	130	165	295	20.55	23.11	21.52
	Brain & nervous system benign	1	1	2	5	4	9	5	10	15	9	18	27	12	22	34	5	12	17	6	16	22	43	83	126	6.65	11.56	9.23
	ALL CANCERS	76	280	356	91	327	418	232	471	703	821	1035	1856	1656	1405	3061	1791	1295	3086	1230	1183	2413	5897	5996	11893	920.84	822.80	855.58
	*Age standardized incidence rate per 100 00	_																										


### **Tumour Staging by Site**

## Staging on sites with more than 40 cases

#### Lip Frequency Percent Stage I 36 72.00 Stage II 6 12.00 Stage III 0 0.00 Stage IV 1 2.00 Unknown 14.00 Total 50 100




Tongue			
	Frequency	Percent	
Stage I	14	27.45	
Stage II	4	7.84	
Stage III	7	13.73	
Stage IV	24	47.06	
Unknown	2	3.92	
Total	51	100	_



#### **Esophagus**

	Frequency	Percent	
Stage I	13	18.06	
Stage II	7	9.72	
Stage III	16	22.22	
Stage IV	29	40.28	
Unknown	7	9.72	
Total	72	100	



#### Stomach

	Frequency	Percent	
Stage I	14	13.73	
Stage II	14	13.73	
Stage III	21	20.59	
Stage IV	43	42.16	
Unknown	10	9.80	
Total	102	100	-



#### Colon excluding rectum

	Frequency	Percent	
Stage I	127	23.09	
Stage II	173	31.45	
Stage III	127	23.09	
Stage IV	109	19.82	
Unknown	14	2.55	
Total	550	100	



#### Rectum & rectosigmoid

	Frequency	Percent	
Stage I	58	21.89	
Stage II	32	12.08	
Stage III	115	43.40	
Stage IV	52	19.62	
Unknown	8	3.02	
Total	265	100	



#### Liver

	Frequency	Percent	
Stage I	24	28.57	
Stage II	12	14.29	
Stage III	23	27.38	
Stage IV	12	14.29	
Unknown	13	15.48	
Total	84	100	



#### **Pancreas**

	Frequency	Percent
Stage I	27	13.37
Stage II	54	26.73
Stage III	21	10.40
Stage IV	92	45.54
Unknown	8	3.96
Total	202	100



<sup>\*</sup> In keeping with international coding conventions, all invasive brain tumors, multiple myeloma and leukemia are considered unstageable using the collaborative staging system utilized by all population-based North American Cancer Registries.

#### Other digestive system

	Frequency	Percent	
Stage I	9	10.47	
Stage II	15	17.44	
Stage III	8	9.30	
Stage IV	27	31.40	
Unknown	27	31.40	
Total	86	100	



#### Lung & bronchus

	Frequency	Percent	
Stage I	239	26.91	
Stage II	58	6.53	
Stage III	173	19.48	
Stage IV	404	45.50	
Unknown	12	1.35	
Occult carcinoma	2	0.23	
Total	888	100	




#### Soft tissue (including heart)

	Frequency	Percent	
Stage I	17	34.00	
Stage II	13	26.00	
Stage III	9	18.00	
Stage IV	8	16.00	
Unknown	3	6.00	
Total	50	100	



#### Melanoma of the skin

	Frequency	Percent	
Stage I	216	72.73	
Stage II	42	14.14	
Stage III	21	7.07	
Stage IV	13	4.38	
Unknown	5	1.68	
Total	297	100	




#### Breast

	Frequency	Percent	
Stage I	364	40.76	
Stage II	341	38.19	
Stage III	109	12.21	
Stage IV	69	7.73	
Unknown	10	1.12	
Total	893	100	



#### **Cervix Uteri**

	Frequency	Percent	
Stage I	24	48.98	
Stage II	15	30.61	
Stage III	9	18.37	
Stage IV	1	2.04	
Unknown	0	0.00	
Total	49	100	



#### **Corpus Uteri**

	Frequency	Percent	
Stage I	211	68.73	
Stage II	25	8.14	
Stage III	33	10.75	
Stage IV	25	8.14	
Unknown	13	4.23	
Total	307	100	



#### Ovary

	Frequency	Percent	
Stage I	17	27.42	
Stage II	4	6.45	
Stage III	28	45.16	
Stage IV	11	17.74	
Unknown	2	3.23	
Total	62	100	<u>-</u>



<sup>\*</sup> In keeping with international coding conventions, all invasive brain tumors, multiple myeloma and leukemia are considered unstageable using the collaborative staging system utilized by all population-based North American Cancer Registries.

#### Other female genital system

	Frequency	Percent	
Stage I	19	39.58	
Stage II	2	4.17	
Stage III	10	20.83	
Stage IV	5	10.42	
Unknown	12	25.00	
Total	48	100	



#### **Prostate**

	Frequency	Percent	
Stage I	60	8.31	
Stage II	440	60.94	
Stage III	82	11.36	
Stage IV	135	18.70	
Unknown	5	0.69	
Total	722	100	-



#### Bladder

	Frequency	Percent	
Stage I	73	45.63	
Stage II	44	27.50	
Stage III	13	8.13	
Stage IV	23	14.38	
Unknown	7	4.38	
Total	160	100	



#### Kidney

	Frequency	Percent	
Stage I	124	54.87	
Stage II	14	6.19	
Stage III	37	16.37	
Stage IV	44	19.47	
Unknown	7	3.10	
Total	226	100	



#### **Thyroid**

	Frequency	Percent	
Stage I	92	59.35	
Stage II	17	10.97	
Stage III	25	16.13	
Stage IV	19	12.26	
Unknown	2	1.29	
Total	155	100	



#### **Hodgkin Lymphoma**

	Frequency	Percent	
Stage I	7	15.91	
Stage II	14	31.82	
Stage III	12	27.27	
Stage IV	11	25.00	
Unknown	0	0.00	
Total	44	100	



#### Non-Hodgkin Lymphoma

	Frequency	Percent	
Stage I	77	23.91	
Stage II	37	11.49	
Stage III	69	21.43	
Stage IV	137	42.55	
Unknown	2	0.62	
Total	322	100	=



<sup>\*</sup> In keeping with international coding conventions, all invasive brain tumors, multiple myeloma and leukemia are considered unstageable using the collaborative staging system utilized by all population-based North American Cancer Registries.

## Deaths by Underlying Cause in Manitoba<sup>1</sup>

	2017		2016		2015				
CAUSES OF DEATH	Number	Rate per MB Health Population	Rate per Statistics Canada Population*	Number	Rate per MB Health Population*	Rate per Statistics Canada Population*	Number	Rate per MB Health Population*	Rate per Statistics Canada Population*
Accidents (V01-X59, Y85-Y86)	422	31.1	31.5	530	39.6	40.2	534	40.4	41.3
Cancer (C00 - C97)	2,456	181.0	183.5	2,801	209.1	212.5	2,764	209.3	213.7
Cerebrovascular Disease (I60 - I69)	561	41.3	41.9	604	45.1	45.8	596	45.1	46.1
Diabetes (E10 - E14)	276	20.3	20.6	319	23.8	24.2	368	27.9	28.5
Diseases of the heart (I00 - I09, I11, I13, I20 - I25, I26 - I51)	1,883	138.8	140.7	2,166	161.7	164.3	2,136	161.8	165.1
Pneumonia (J12-J18)	184	13.6	13.8	237	17.7	18.0	228	17.3	17.6
Intentional Self-Harm (X60 - X84, Y890)	166	12.2	12.4	193	14.4	14.6	173	13.1	13.4

#### Reference

<sup>1</sup>Vital Statistics Agency, 2017/18 Annual Report. Government of Manitoba; 2018. [cited April 28, 2022]. http://vitalstats.gov.mb.ca/pdf/2017\_vs\_annual\_report\_en.pdf

### Appendix 1

### INTERNATIONAL CLASSIFICATION OF DISEASES FOR ONCOLOGY **3rd Edition**

PRIMARY SITE	SITE/ CELL TYPE	
Buccal cavity and pharynx	C00:C14	
Lip	C000:C009	
Tongue	C019:C029	
Major salivary gland	C079:C089	
Floor of mouth	C040:C049	
Gum & other mouth	C030:C039, C050:C059, C060:C069	
Nasopharynx	C110:C119	
Oropharynx	C100:C109	
Hypopharynx	C129, C130:C139	
Other buccal cavity & pharynx	C090:C099, C140, C142:C148	
Digestive system	(15:(26	
Esophagus	C150:C159	
Stomach	C160:C169	
Small intestine	C170:C179	
Colon excluding rectum	C180:C189, C260	
Rectum & Rectosigmoid	C199, C209	
Anus	C210:C212, C218	
Liver	C220	
Gallbladder	C239	
Pancreas	C250:C259	
Other digestive system	C240:C249, C221, C480, C481:C482, C268:C269	
	(488	
Respiratory system	C30:C39	
Larynx	C320:C329	
Lung & bronchus	C340:C349	
Other respiratory system	C300:C301, C310:C319, C384, C339, C381:C383	
	C388, C390:C399	
Bones & joints	C400:C419	
Soft tissue (including heart)	C380, C470:C479, C490:C499	
Mesothelioma	9050:9055	
Kaposi sarcoma	9140	
Skin	C44	
Melanomas of the skin	C440:C449 ( 8720:8790)	
Other skin	C440:C449	
Breast	C500:C509	
Female genital system	C51:C58	
Cervix uteri	C530:C539	
Corpus uteri	C540:C549	
Uterus, NOS	C559	
Ovary	C569	

PRIMARY SITE	SITE/ CELL TYPE
Male genital system	C60:C63
Prostate	C619
Testis	C620:C629
Penis	C600:C609
Other male genital system	C630:C639
Urinary system	C64:C68
Bladder (incl. in situ)	C670:C679
Kidney and renal pelvis	C649, C659
Ureter	C669
Other urinary system	C680:C689
Eye	C690:C699
Brain & other nervous system	C70:C72
Brain	C710:C719
Other nervous system	C710:C719 ( 953), C700:C709. C720:C729
Endocrine	C73:C75
Thyroid	C739
Other endocrine	C379, C740:C749, C750:C759
Lymphomas	
Hodgkin lymphoma	9650-9667
Non-Hodgkin lymphoma	9590-9597, 9670-9671, 9673, 9675, 9678-9680, 9684, 9687-9691, 9695, 9698-9702, 9705, 9708-9709, 9712, 9714-9719, 9724-9729, 9735, 9737, 9738
Myeloma	9811-9818 (except C420, C421, C424) 9823 (except C420, C421, C424) 9827 (except C420, C421, C424) 9837 (except C420, C421, C424) 9731-9732, 9734
Leukemias	C42
Acute lymphocytic	9826, 9835-9836 9811-9818 (only C421) 9837 (only C421)
Chronic lymphocytic	9823 (only C421, if SLL C77)
Acute myeloid	9840, 9861, 9865-9867, 9869, 9871-9874, 9895- 9897, 9898, 9910-9911, 9920,
Acute monocytic	9891
Chronic myeloid	9863, 9875-9876, 9945-9946
Other	9733, 9742, 9800, 9801, 9805-9809, 9820, 9831- 9834, 9860, 9870, 9930, 9931, 9940, 9948, 9963, 9964 9827 (only C421)
Other, ill-defined, & unknown	9740-9741, 9750-9769, 9950, 9960-9962, 9965- 9967, 9970-9971, 9975, 9980, 9982-9987, 9989, 9991-9992 C420-C424 (except 9050-9055, 9140, 9590-9992) C760-C768 (except 9050-9055, 9140, 9590-9992) C770-C779 (except 9050-9055, 9140, 9590-9992)

#### **CONTACT DETAILS**

Room ON2114 675 McDermot Ave. Winnipeg, MB R3E oV9 Main line: (204) 787-2174

#### TO CITE THIS REPORT

Department of Epidemiology and Cancer Registry, CancerCare Manitoba. "Cancer in Manitoba, 2017 Annual Statistical Report."

Find the Department of Epidemiology and Cancer Registry and data request guidelines online under the Research tab at www.cancercare.mb.ca

